Products & ReviewLife Sciences
AZD8055
mTOR pathway inhibitor; Inhibits mTOR
AZD8055
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
AZD8055 is a potent, selective ATP-competitive inhibitor of mammalian target of rapamycin (mTOR), with an IC₅₀ value of 0.8 nM (Chresta et al.). It is very specific with ~1,000-fold selectivity for mTOR over all PI3K isoforms and exhibits no activity against a panel of 260 kinases at concentrations up to 10 µM (Chresta et al.).
CANCER RESEARCH
- Inhibits proliferation of A549 and H838 small-cell lung cancer cell lines in vitro, and inhibits tumor growth from a variety of human tumor xenografts in mice after oral administration (Chresta et al.).
- Inhibits cell proliferation, increases cell death and reduces migration in tamoxifen-resistant (TamR) and estrogen deprivation-resistant (MCF7-X) breast cancer cell lines (Jordan et al.).
- Induces apoptosis and inhibits proliferation in Hep-2, a human laryngeal cancer cell line (Zhao et al.).
- In combination with ABT-737, synergistically induces apoptosis in rhabdomyosarcoma (RMS) cells by suppressing expression of myeloid leukemia cell differentiation protein (MCL1; Preuss et al.).
- Inhibits proliferation and glycolysis, and induces apoptosis, in HeLa human cervical cancer cell line (Li et al.).
